502 related articles for article (PubMed ID: 27068948)
1. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.
Yeku OO; Brentjens RJ
Biochem Soc Trans; 2016 Apr; 44(2):412-8. PubMed ID: 27068948
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
3. Development of CAR T cells designed to improve antitumor efficacy and safety.
Jaspers JE; Brentjens RJ
Pharmacol Ther; 2017 Oct; 178():83-91. PubMed ID: 28342824
[TBL] [Abstract][Full Text] [Related]
4. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
Chmielewski M; Hombach AA; Abken H
Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
[TBL] [Abstract][Full Text] [Related]
5. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
Lo AS; Ma Q; Liu DL; Junghans RP
Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
[TBL] [Abstract][Full Text] [Related]
6. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.
Curran KJ; Seinstra BA; Nikhamin Y; Yeh R; Usachenko Y; van Leeuwen DG; Purdon T; Pegram HJ; Brentjens RJ
Mol Ther; 2015 Apr; 23(4):769-78. PubMed ID: 25582824
[TBL] [Abstract][Full Text] [Related]
7. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
8. Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells.
Cheadle EJ; Rothwell DG; Bridgeman JS; Sheard VE; Hawkins RE; Gilham DE
Gene Ther; 2012 Nov; 19(11):1114-20. PubMed ID: 22130449
[TBL] [Abstract][Full Text] [Related]
9. Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma.
Kintz H; Nylen E; Barber A
Cell Immunol; 2020 May; 351():104069. PubMed ID: 32106933
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L
Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900
[TBL] [Abstract][Full Text] [Related]
11. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling.
Hombach AA; Abken H
Int J Cancer; 2011 Dec; 129(12):2935-44. PubMed ID: 22030616
[TBL] [Abstract][Full Text] [Related]
12. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Cherkassky L; Morello A; Villena-Vargas J; Feng Y; Dimitrov DS; Jones DR; Sadelain M; Adusumilli PS
J Clin Invest; 2016 Aug; 126(8):3130-44. PubMed ID: 27454297
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?
Alonso-Camino V; Harwood SL; Álvarez-Méndez A; Alvarez-Vallina L
Biochem Soc Trans; 2016 Apr; 44(2):406-11. PubMed ID: 27068947
[TBL] [Abstract][Full Text] [Related]
14. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
15. Approaches to augment CAR T-cell therapy by targeting the apoptotic machinery.
Karlsson H
Biochem Soc Trans; 2016 Apr; 44(2):371-6. PubMed ID: 27068942
[TBL] [Abstract][Full Text] [Related]
16. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
[TBL] [Abstract][Full Text] [Related]
18. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
19. [Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].
Xu XJ; Zhao HZ; Tang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):521-5. PubMed ID: 23628068
[TBL] [Abstract][Full Text] [Related]
20. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
